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ABSTRACT
Objective: The objective of the study was to identify the potential lead phytochemical compounds that can be targeted against the severe acute 
respiratory coronavirus, 2019 (SARS-CoV-19) main protease (6LU7).
Method: A total of 191 phytochemicals from the Phytochemical and Drug Target Database (PDTDB) were retrieved and screened against SARS-CoV-19 
protease by employing computational molecular docking studies.
Results: Our molecular docking results reveal that compounds ergosterol peroxide, punicalin, oleanolic acid, naringin, and diosmin are showing a 
very good affinity for coronavirus disease, 2019 (COVID-19) main protease and can be explored further as the lead candidate.
Conclusion: Computational studies of phytochemicals library against 6LU, a SARS-CoV-19 main protease led to the determination of compounds with 
the best theoretical affinity. Further, more target information of these compounds is needed for drug intervention, rational drug design, in vitro and 
in vivo evaluations, and final preparation in terms of clinical trial so that they can be used to combat the novel virus SARS-CoV-19.
Keywords: Coronavirus, COVID-19 main protease, Phytochemicals, Molecular Docking, Receptor-ligand Interaction AutoDock Vina, Chimera 1.13.1, 
Discovery studio.
INTRODUCTION
One of the worst viral outbreaks that have become a reason for 
everyone’s concern is contagiously spreading coronavirus disease, 2019 
(COVID-19). Severe acute respiratory coronavirus, 2019 (SARS-CoV-19), 
a zoonotic virus having an incubation period of 2–14 days, was reported 
causing a cluster of pneumonia cases in Wuhan city, Hubei Province of 
China. The outbreak has caused havoc globally by affecting 213 countries 
and territories along with two international conveyances. Worldwide, a 
total of 5,403,979 COVID-19 cases were reported as of May 24, 2020, and 
343,975 people have died. Symptoms of COVID-19 include respiratory 
problems, fever, cough, shortness of breath, and dyspnea. In more severe 
cases, the infection can cause pneumonia, severe acute respiratory 
syndrome, kidney failure, and even death [1]. Unfortunately, there are 
no specific effective therapies available for treating COVID-19.
Genetic sequence analysis reveals that it is closely related to 
coronavirus found in bats [2]. Coronavirus (CoVs) belongs to the 
Coronaviridae family of the order Nidovirales which are divided into 
four genera (α, β, γ, and δ) [3]. Viruses of the family Coronaviridae 
possess a single-stranded, positive-sense RNA genome ranging from 
26 to 32 kb in length [4]. CoVs contain four structural proteins: 
Spike (S) protein, envelope (E) protein, membrane (M) protein, and 
nucleocapsid (N) protein [5]. The known proteases of SARS-CoV-19 
include viral papain-like protease (PLpro), main protease (3CLpro, 
also named as 3-chymotrypsin-like protease), RNA-dependent RNA 
polymerase (RdRp), helicase, and spike [6]. One of the best strategies 
to treat SARS-CoV-2 is to target the main proteases encoded by it. 
Among all of the proteases found in SARS-CoV-19, 3CLpro, the main 
protease plays an important role in the viral invasion by aiding in the 
maturation of non-structural protein, making it an attractive target 
for COVID-19 drug development. The main protease 6LU7 is a 3CLpro 
monomer and it consists of three domains, domain I (residues 8-101), 
domain II (residues 102-184), and domain III (residues 201-303), and 
a long loop (residues 185-200) that connects domains II and III. The 
active site of 3CLpro is located in the gap between domains I and II and 
has a CystHis catalytic dyad (Cyst145 and His41, as shown in Fig. 1) [7]. 
This catalytic site is of significance and can be used for finding small 
molecules that can bind and further, prevent viral molecular pathology.
Treatment using natural products remains a plausible option in terms 
of a control mechanism as specific vaccines and antiviral agents will 
take time because of epitope shifting in SARS-CoV-2. The effectiveness 
of herbal treatment to control contagious disease was demonstrated 
during the 2003 SARS outbreak [8] Shuanghuanglian, a Chinese herbal 
medicine that contains extracts from the dried fruit Lian Qiao (Forsythia 
Fructus), has been reported for treating infections for more than 2000 
years [9]. Hence, this study focuses on the importance of medicinal 
plants and their constituents to identify the lead compound for treating 
COVID-19.
METHODOLOGY
The 3D structure of 191 phytochemicals was downloaded from 
the Phytochemical and Drug Target Database (PDTDB) [10] and 
screened by employing a structure-based virtual screening method. 
The X-ray crystal structure of SARS-CoV-19 main protease, a potent 
target for coronavirus disease, was retrieved from Protein Data 
Bank (http://www.rcsb.org/structure/6LU7). Target receptors were 
prepared for docking by removing undesirable bound ligand and 
water molecules using UCSF Chimera [11]. Hydrogen atoms, Gasteiger 
charges, were added to every atom of the receptors and finally 
converted into PDBQT format for docking. The structure of investigated 
phytochemicals was minimized using Open Babel software [12] and for 
final conversion into PDBQT format for docking. The virtual screening 
was performed using AutoDock Vina [13] wizard of PyRx [14]. Docking 
was performed using Lamarckian genetics as a scoring algorithm. 
For each docked molecule, AutoDock Vina showed different binding 
positions so, among them, we have selected the best conformation with 
the best energy score, i.e., low binding affinity (Kcal/mol). The result of 
docking and protein-ligand interaction was visualized using the Biovia 
Discovery Studio software [15]. This software helps in 3D visualization 
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of amino residue interaction, binding pocket, and the forces involved in 
the ligand binding.
RESULTS AND DISCUSSION
The emergence and contagious spread of COVID-19 have posed 
complex challenges to the public health, research, and medical 
communities which have led to attempts for combined drug therapy 
directed against its various targets but, unfortunately, there is no 
registered medical treatment for the zoonotic virus as of now. Various 
computational studies have been carried out and are believed to be of 
immense potential. Especially, the use of phytochemicals as a target 
against SARS-CoV-19 remains a point of interest due to their good 
medical history. Our high throughput virtual screening study done 
using 191 phytochemicals against COVID-19 protease (6LU7) reveals 
that 13 compounds are showing a binding affinity of ≤−8 Kcal/mol (the 
binding affinity of top 20 compounds is shown in Table 1).
Further, we have also tried to explore the molecular interactions 
involved in the binding of the top 5 phytochemicals (ergosterol 
peroxide, punicalin, oleanolic acid, naringin, and diosmin) with the 
amino acid residues present in the binding pocket of the SARS-CoV-19 
main protease. Hydrogen bond, van der Waals force, and pi-pi 
interaction were the main interaction forces involved in the binding, as 
summarized in Figs. 2 and 3.
Docking studies constitute an important role in finding out the binding 
affinity of the ligand to a particular target, the conformation of the 
ligand bound to a macromolecule, and the appropriate target binding 
site, thus increasing the accuracy which forms the basis of rational drug 
design. Several studies highlighting the importance of phytocompounds 
and natural herbs have been reported in the literature. A randomized, 
double-blind study was conducted for evaluating the effect of natural 
herbal medicine composition on SARS and included herbs such as 
Gypsum fibrosum, Bupleurum chinense, Gardenia jasminoides, and Siler 
divaricatum [16]. Deng-hai Zhang et al. reported more than 20 Chinese 
herbal medicines showing antiviral and inflammatory responses 
using an in silico study to combat SARS-CoV-19 [8]. Indian herbal 
Fig.1: (a) Crystal structure of SARS-CoV-19 main protease 
(PDB ID-6LU7); (b) representation of catalytic dyad formed by 
cysteine-145 and histidine-41 residues in the binding pocket of 
SARS-CoV-19 main protease
ba
Fig. 2: Interaction of phytochemicals with the active site residue of SARS-CoV-19 main protease (6LU7). (a) Ergosterol peroxide. (b) 2D 
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medicines have always been relied on as the representatives of the field 
of traditional medicines [17,18]. Recently, the Ministry of AYUSH has 
also emphasized on developing drugs using natural compounds from 
ayurvedic medicinal herbal plants for treating COVID-19. By conducting 
this study, we have been successful in identifying five natural 
compounds showing good binding affinity against the SARS-CoV-19 
protease (6LU7).
Lead phytochemicals and their medicinal use
The top 5 potential lead phytochemicals include ergosterol peroxide, 
punicalin, oleanolic acid, naringin, and diosmin. Ergosterol peroxide is 
a C28 sterol, isolated from Ganoderma lucidum and Cordyceps sinensis 
which are a type of fungus [19]. Several beneficial biological effects of 
this compound, such as antimicrobial, cytotoxic, and immunosuppressive 
activities, have been reported [19]. Its role as a metabolite, an 
antineoplastic agent, an antibacterial drug, and a trypanocidal drug, 
has also been mentioned. Punicalin is found in edible sources such as 
Punica granatum, i.e., pomegranate along with plants such as Combretum 
glutinosum and Terminalia catappa which is used to treat dermatitis and 
hepatitis [20]. It has been used to treat several complications including 
parasitic and microbial infections, diarrhea, hemorrhage, and respiratory 
problems [21]. The rich source of oleanolic acid is Olea europaea,Rosa 
woodsii (leaves), Prosopis glandulosa (leaves and twigs), and Phoradendron 
juniperinum (whole plant) [22]. Oleanolic acid exhibits hepatoprotective, 
antitumor, and antiviral properties [19]. Another compound with 
beneficial biological properties is naringin which is a flavone glycoside 
found in grapes and citrus fruits. It also has a role as an anti-inflammatory 
agent, antineoplastic agent, and blood lipid-lowering agent [23]. Diosmin 
is a natural flavone that is abundant in the pericarp of various citrus 
fruits. It acts as an antioxidant, antihyperglycemic, anti-inflammatory, 
antimutagenic, and antiulcer agent [24,25]. These compounds showing 
good binding affinity have been known for their various therapeutic and 
medicinal properties and our study highlighted their potential to conquer 
SARS-CoV-19 by interacting with its main protease.
CONCLUSION
Several attempts have been made to treat COVID-19 by combined drug 
therapy directed against its targets and also various clinical trials have 
been initiated. The use of natural compounds has a successful history in 
treating SARS which occurred in 2003. Hence, virtual screening of the 
natural compounds was really of great significance in discovering the 
compound with the best binding affinity against one of the important 
targets of SARS-CoV-19 main protease. Our virtual screening shows that 
ergosterol peroxide, a compound from fungal origin, has the potential to be 
tested further by in vitro and in vivo studies for the treatment of COVID-19.
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Table 1: Binding affinity of top 20 phytochemicals against 
SARS-CoV-19 main protease (6LU7)
S. No. Phytochemical compound Binding affinity 
(Kcal/mol)
1. Ergosterol peroxide −8.8
2. Punicalin −8.6









9. Ursolic acid −7.9
10. Avicularin −7.8
11. Deoxycalyxin A −7.7





17. 2,5-Dihydroxybenzoic acid −7.1
18. Pyridoxine −7
19. Menthofuran −6.9
20. Geranic acid −6.8
Fig. 3: Interaction of phytochemicals with the active site residues of SARS-CoV-19 main protease (6LU7). (a) Oleanolic acid. (b) Naringin. 
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